• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Intraday Session

    8/22/23 1:31:17 PM ET
    $ARAV
    $ARMP
    $CNSP
    $EUDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARAV alert in real time by email

    Gainers

    • Fulcrum Therapeutics (NASDAQ:FULC) stock rose 43.4% to $5.62 during Tuesday's regular session. Fulcrum Therapeutics's stock is trading at a volume of 68.5 million shares as of 13:31 EST. This is 9987.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $347.4 million.
    • Regencell Bioscience (NASDAQ:RGC) shares increased by 28.57% to $18.0. The market value of their outstanding shares is at $234.2 million.
    • CNS Pharma (NASDAQ:CNSP) stock rose 24.81% to $1.52. As of 13:31 EST, this security is trading at a volume of 670.2K shares, making up 152.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.3 million.
    • EUDA Health Holdings (NASDAQ:EUDA) shares increased by 19.1% to $0.94. As of 13:31 EST, EUDA Health Holdings's stock is trading at a volume of 327.3K, which is 191.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $23.0 million.
    • Nanoviricides (AMEX:NNVC) shares moved upwards by 17.75% to $1.64. Trading volume for Nanoviricides's stock is 151.5K as of 13:31 EST. This is 149.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $19.1 million.
    • Renovaro Biosciences (NASDAQ:RENB) shares moved upwards by 13.88% to $2.05. Renovaro Biosciences's stock is trading at a volume of 424.4K shares as of 13:31 EST. This is 11.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $130.5 million.

    Losers

    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock fell 29.2% to $0.17 during Tuesday's regular session. As of 13:31 EST, this security is trading at a volume of 4.4 million shares, making up 179.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.4 million.
    • Aravive (NASDAQ:ARAV) shares fell 25.32% to $0.15. Aravive's stock is trading at a volume of 6.7 million shares as of 13:31 EST. This is 269.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.1 million. As per the press release, Q2 earnings came out yesterday.
    • Armata Pharmaceuticals (AMEX:ARMP) shares declined by 20.92% to $2.85. Armata Pharmaceuticals's stock is trading at a volume of 86.6K shares as of 13:31 EST. This is 53.4% of its average full-day volume over the last 100 days. The company's market cap stands at $103.1 million.
    • Tivic Health Systems (NASDAQ:TIVC) stock declined by 18.65% to $0.05. As of 13:31 EST, this security is trading at a volume of 55.3 million shares, making up 154.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.0 million.
    • Nexalin Technology (NASDAQ:NXL) shares decreased by 18.47% to $0.49. The current volume of 109.0K shares is 432.5% of Nexalin Technology's average full-day volume over the last 100 days (last updated at 13:31 EST). The company's market cap stands at $3.6 million.
    • T2 Biosystems (NASDAQ:TTOO) stock declined by 17.11% to $0.44. As of 13:31 EST, this security is trading at a volume of 66.9 million shares, making up 63.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $145.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARAV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARAV
    $ARMP
    $CNSP
    $EUDA

    CompanyDatePrice TargetRatingAnalyst
    Fulcrum Therapeutics Inc.
    $FULC
    1/12/2026$20.00Overweight
    Analyst
    NanoViricides Inc.
    $NNVC
    12/16/2025Buy
    Alliance Global Partners
    Fulcrum Therapeutics Inc.
    $FULC
    11/24/2025Buy
    Truist
    Fulcrum Therapeutics Inc.
    $FULC
    7/29/2025$4.00 → $12.00Neutral → Buy
    H.C. Wainwright
    Fulcrum Therapeutics Inc.
    $FULC
    5/23/2025$12.00Market Perform → Outperform
    Leerink Partners
    Fulcrum Therapeutics Inc.
    $FULC
    5/15/2025$10.00Neutral → Overweight
    Cantor Fitzgerald
    Fulcrum Therapeutics Inc.
    $FULC
    9/13/2024$17.00 → $4.00Buy → Neutral
    H.C. Wainwright
    Fulcrum Therapeutics Inc.
    $FULC
    9/12/2024$15.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    More analyst ratings

    $ARAV
    $ARMP
    $CNSP
    $EUDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Kyme Pierre covered exercise/tax liability with 1,030 shares, decreasing direct ownership by 10% to 9,461 units (SEC Form 4)

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    3/17/26 7:48:27 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Birx Deborah covered exercise/tax liability with 4,919 shares, decreasing direct ownership by 2% to 212,458 units (SEC Form 4)

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    3/17/26 7:46:39 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Kramer Robin

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    3/11/26 9:18:25 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARAV
    $ARMP
    $CNSP
    $EUDA
    SEC Filings

    View All

    Tivic Health Systems Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/13/26 5:27:44 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic Health Systems Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events

    8-K - Tivic Health Systems, Inc. (0001787740) (Filer)

    3/11/26 5:15:25 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    CNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)

    3/11/26 8:35:29 AM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $ARMP
    $CNSP
    $EUDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Fulcrum Therapeutics with a new price target

    Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00

    1/12/26 8:13:43 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on NanoViricides

    Alliance Global Partners initiated coverage of NanoViricides with a rating of Buy

    12/16/25 8:59:58 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Fulcrum Therapeutics

    Truist initiated coverage of Fulcrum Therapeutics with a rating of Buy

    11/24/25 8:30:36 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $ARMP
    $CNSP
    $EUDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

    4 - Nexalin Technology, Inc. (0001527352) (Issuer)

    3/13/25 4:52:26 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Medical Officer Owens David bought $3,100 worth of shares (1,000 units at $3.10), increasing direct ownership by 0.65% to 155,793 units (SEC Form 4)

    4 - Nexalin Technology, Inc. (0001527352) (Issuer)

    2/5/25 3:17:26 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Medical Officer Owens David bought $2,980 worth of shares (1,000 units at $2.98), increasing direct ownership by 0.65% to 154,793 units (SEC Form 4)

    4 - Nexalin Technology, Inc. (0001527352) (Issuer)

    2/4/25 5:05:25 PM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARAV
    $ARMP
    $CNSP
    $EUDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to one new employee. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4). Fulcrum granted the new employee 34,000 options to pur

    3/6/26 4:30:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

    SINGAPORE, March 04, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ:EUDA) ("EUDA" or the "Company"), a Singapore based non-invasive healthcare provider in Asia focused on Singapore, Malaysia and China, today announced that it has repurchased and cancelled in full the warrant previously issued to Streeterville Capital, LLC. Background of the Warrant As previously disclosed, the Company entered into a securities purchase agreement dated November 26, 2025 with an accredited investor for the purchase of a warrant that was immediately exercisable into up to 2,000,000 newly issued ordinary shares of the Company. The warrant was previously amended on December 16, 2025 and Januar

    3/4/26 9:10:00 AM ET
    $EUDA
    Medical/Nursing Services
    Health Care

    Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

    CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the "Company") (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m. ET. The webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics' website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics' webs

    3/3/26 8:30:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARAV
    $ARMP
    $CNSP
    $EUDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by CNS Pharmaceuticals Inc.

    SC 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)

    11/14/24 3:58:53 PM ET
    $CNSP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by T2 Biosystems Inc.

    SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

    11/14/24 3:38:45 PM ET
    $TTOO
    Medical/Dental Instruments
    Health Care

    $ARAV
    $ARMP
    $CNSP
    $EUDA
    Leadership Updates

    Live Leadership Updates

    View All

    Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

    HOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. ("Carmi Masha"), a leading Israeli medical device distributor, to market and sell Nexalin's Gen-2 Console ("SYNC"), 15 milliamp (mA), non-invasive frequency-based neurostimulation device throughout Israel. This agreement follows the recent regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of Nexalin's Gen-2 SYNC device in Israel for the treatment of a var

    11/13/25 9:15:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that CEO, Jennifer Ernst, will participate in the eighth annual Constellation Forum, a global conversation on Bioelectronic Medicine. She will join other leaders in the field to discuss the opportunities for advancing bioelectronic medicine. When: Thursday, Oct. 23, at 11:55 a.m. ET/8:55 a.m. PT Panel Title: Building a Big Tent Bioelectronic Medicine stands to disrupt how we diagnose, treat, and manage disease, but fulfilling that promise requires broad alignment across the healthcare ecosystem. This session will explore how to rally the global community,

    10/22/25 2:00:00 PM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

    HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin"), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin's strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer's disease and Traumatic Brain Injury (TBI). In anticipation of the Company's new FDA submissions, Dr. Rothstein will support Nexalin's preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein bring

    10/13/25 8:30:00 AM ET
    $NXL
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ARAV
    $ARMP
    $CNSP
    $EUDA
    Financials

    Live finance-specific insights

    View All

    Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    ― Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically relevant response, with progression toward pan-cellular HbF induction as F-cells increased from 31% to 63% ― ― 7 of 12 patients (58%) achieved absolute HbF levels ≥20%; all patients achieved at least a 6.5% absolute increase in HbF ― ― Improvements in markers of hemolysis, improved erythropoiesis, and a >1 g/dL increase in total hemoglobin ― ― 7 of 12 patients (58%) reported zero VOCs during the treatment period ― ― Pociredir was generally well-tolerated, with no treatment-related serious adverse events (SAEs) ― ― Fulcrum plans to initiate a pote

    2/24/26 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

    CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, will host a conference call and webcast on Tuesday, February 24, 2026 beginning at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease. Members of Fulcrum management will be joined by Dr. Martin Steinberg, Professor of Medicine, Pediatrics, Pathology and Laboratory Medicine at Boston University Chobanian and Avedisian School of Medicine. To register for

    2/17/26 8:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tivic Health to Report Third Quarter 2025 Financial Results on November 14th Via Conference Call and Webcast

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified immunotherapeutics company, today announced that it will report its third quarter results for 2025 via pre-recorded conference call and webcast on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET. Teleconference Details: Toll Free: 888-506-0062 International: 973-528-0011 Participant Access Code: 230582 Webcast Link https://www.webcaster5.com/Webcast/Page/2865/53145 About Tivic Health Systems, Inc. Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell

    11/6/25 9:30:00 AM ET
    $TIVC
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care